Combination therapy for advanced colorectal cancer with liver spread
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two medicines, pin and sintilimab, for people with advanced colorectal cancer that has spread to the liver and has already been treated with at least two standard therapies. The study aims to see if injecting the medicine directly into the liver tumor, combined with immunotherapy through a vein, can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have colorectal cancer that has spread to the liver and has not responded to at least two earlier treatments.
- The cancer must be a type called pMMR or MSS (your doctor can check).
- You must have at least one liver tumor that can be directly injected with the study medicine, and another tumor that can be measured on scans.
- You must be willing to have a new biopsy of the tumor during the study.
- Your overall health must be good enough for treatment, with acceptable blood counts, liver and kidney function, and heart health.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment combining a drug called PIN with an immunotherapy (anti-PD1) for people with advanced liver cancer (HCC) that has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or control the disease.
This trial tests a new combination of two drugs (PIN plus an anti-PD1 immunotherapy) for people with advanced solid tumors that either did not respond to standard treatment or have tumor types known to have low response to immunotherapy, like liver cancer. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two drugs (anlotinib and sintilimab) as a first treatment for people with advanced colorectal cancer that has spread to places other than the liver, who do not want chemotherapy. The goal is to see if this targeted therapy can help control the cancer.
This trial tests a combination of two extra drugs (pirfenidone and sintilimab) added to standard chemotherapy before surgery. The goal is to see if this combination can help shrink or control colorectal cancer that has spread to the lining of the abdomen.
This trial tests a combination of two drugs, sintilimab (an immunotherapy that helps the immune system fight cancer) and gossypol acetate (a drug that may make cancer cells more vulnerable), for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can slow or stop the cancer.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.